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1022-80 Safety and Feasibility of Paclitaxel-Eluting Stents in the 
Treatment of ST-Elevation Acute Myocardial Infarction
Andrew T. L Ong, Pedro A. Lemos, Angela Hoye, Chourmouzios A. Arampatzis, 
Francesco Saia, Jiro Aoki, Carlos van Mieghem, Sjoerd H. Hofma, Pieter C. Smits, 
Willem J. van der Giessen, Georgios Sianos, Eugene McFadden, Pim de Feyter, Patrick 
W. Serruys, Thoraxcenter, Rotterdam, The Netherlands
Background: Paclitaxel-eluting stents (PES) have been shown to markedly reduce rest-
enosis in elective patients. To date, there have been no studies evaluating their role in the
treatment of ST-Elevation Myocardial Infarction.
Method: Paclitaxel-eluting stents have been utilised as the default strategy for all patients
at our institution as part of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital
(T-SEARCH) Registry. Patients who received other types of drug eluting stents were not
eligible for the registry. From 10 March 2003 to 11 July 2003, ninety seven consecutive
patients were treated for ST elevation acute myocardial infarction with at least one PES.
One patient was excluded from the analysis as his acute myocardial infarction was sec-
ondary to subacute thrombosis.
Results: Seventy-eight patients underwent primary PCI while the remainder were treated
following failed thrombolytic therapy. Multi vessel disease was present in 39% of patients,
with an average of 1.26 vessels treated per patient. The RCA and LAD accounted for
44% and 39% of vessels treated respectively. Forty one percent of patients received gly-
coprotein IIb/IIIa inhibitors.
Subacute thrombosis was seen in one patient an hour after the index procedure while a
second patient required thrombolytic therapy for new ST elevation four days after the
index procedure. A further two patients developed symptoms four and six days following
bifurcation stenting. These patients had angiographic evidence of subacute thrombosis.
Six-month follow-up data will be available for these patients at the time of presentation.
Conclusion: This is the first study to evaluate the safety and feasibility of PES in the set-
ting of acute myocardial infarction. Bifurcation stenting in acute myocardial infarction
appears to predispose to the development of subacute stent thrombosis.
1022-81 Short Door-to-Balloon Times With Primary 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction Improve Late Survival in Patients 
With Early, but Not Late Presentation
Bruce R. Brodie, Thomas D. Stuckey, Charles J. Hansen, Debra S. VerSteeg, Denise B. 
Muncy, Navin Gupta, William Downey, LeBauer Cardiovascular Research Foundation 
and Moses Cone Heart and Vascular Center, Greensboro, NC, NC
Background: The importance of door-to-balloon time (DBT) with primary PCI for AMI is
controversial.
Methods: Consecutive pts (n=2,117) with ST-segment elevation AMI treated with pri-
mary PCI were prospectively enrolled in a registry and followed clinically for 6.5 years
(mean).
Results: DBT (<1.5 vs >1.5-2 vs >2-3 vs >3 hrs) was highly correlated with in-hospital
mortality (5.2% vs 7.0% vs 11.4% vs 14.2%, p<0.0001) and late cardiac mortality (23.3%
vs 25.8% vs 30.0% vs 34.7%, p<0.0001). After adjusting for differences in baseline vari-
ables, DBT >2 hrs was a strong independent predictor of late mortality (OR 1.31 95% CI
1.07-1.61, p=0.008). However, prolonged DBT (>2 hrs) was associated with increased
mortality only in patients presenting early (<2 hrs) (n=891) (OR 1.32 95% CI 1.08-1.62,
p=0.007), and had little effect on mortality in patients presenting late (>2 hrs) (n=1206)
(OR 1.17 95% CI 0.82-1.67, p=0.39)
Conclusion: Rapid time to treatment with primary PCI improves late survival in patients
presenting early but is less critical in patients presenting late. These data are consistent
with previous observations that there is a window of opportunity during which early reper-
fusion with primary PCI can result in superior outcomes, after which further delays in
treatment have much less effect on mortality. These observations have implications
regarding the triage of patients for primary PCI. 
1022-82 A Prospective, Randomized Trial of Mild Hypothermia 
During Primary Percutaneous Intervention for Acute 
Myocardial Infarction (COOL-MI): One-Year Clinical 
Outcome
Simon R. Dixon, David G. Rizik, John J. Griffin, Joseph P. Carrozza, Barry D. Rutherford, 
Adnan Kastrati, Suku T. Thambar, Richard E. Kuntz, Raymond J. Gibbons, Jeffrey J. 
Popma, William W. O'Neill, The COOL-MI Investigators, William Beaumont Hospital, 
Royal Oak, MI, Sentara Virginia Beach General Hospital, Sentara, VA
Background: Mild hypothermia reduces infarct size in experimental models of acute
myocardial infarction (AMI). We conducted a prospective, randomized trial to evaluate the
safety and efficacy of mild hypothermia as an adjunct to primary percutaneous coronary
intervention (PCI) for AMI.
Methods: Three hundred-fifty seven patients with acute ST-segment elevation MI (<6-
hours from symptom-onset) were assigned to undergo primary PCI with or without
adjunctive cooling. Hypothermia was induced using the ReprieveTM Endovascular Tem-
perature Therapy System (Radiant Medical Inc., Redwood City, CA). Patients were
cooled to a target core temperature of 33oC for 3 hours after reperfusion. The primary
effectiveness endpoint of the trial was final infarct size at 30-days measured using 99mTc-
sestamibi SPECT imaging. The primary safety endpoint was major adverse cardiac
events (MACE) at 30-days. Clinical follow-up was performed at 6 and 12-months.
Results: One hundred seventy-seven patients were randomized to PCI with adjunctive
hypothermia. The mean duration of cooling before reperfusion was 18 minutes (mean
core temperature at first balloon inflation = 35oC). 72% patients reached the target core
temperature (mean time to target = 75 minutes). Cooling was well tolerated. There were
no significant adverse clinical events related to endovascular cooling. Final infarct size in
the hypothermia group was not significantly different from the control group (14.1% vs.
13.8%, p=0.83). MACE at 30-days was similar in both groups (cooling 6.2% vs. control
3.9%, p=0.45). Patients with anterior infarction who had a core temperature of <35oC at
reperfusion had a significantly smaller infarct size compared to both those patients with a
temperature >35oC at reperfusion (9.3% vs. 21.9%, p=0.01), and controls (9.3% vs.
18.2%, p=0.05). Late clinical follow-up is in currently progress.
Conclusion: Endovascular cooling is safe and well tolerated during mechanical reperfu-
sion for AMI. One-year clinical outcome data will be presented for the overall patient pop-
ulation, and the anterior infarct subgroup with a temperature <35oC at reperfusion in
which a reduction in infarct size was observed.
1022-83 The Impact of Insulin-Requiring Diabetes Mellitus on 
Effectiveness of Reperfusion and Outcome of Patients 
Undergoing Primary Percutaneous Coronary 
Intervention for Acute Myocardial Infarction
David Antoniucci, Renato Valenti, Angela Migliorini, Guido Parodi, Guia Moschi, Gentian 
Memisha, Giovanni M. Santoro, Giampaolo Cerisano, Careggi Hospital, Florence, Italy
Background Diabetes mellitus (DM) independently predicts mortality after thrombolytic
therapy for acute myocardial infarction (AMI), while previous studies on outcome of dia-
betics undergoing primary percutaneous coronary intervention (PCI) for AMI did not con-
firm the relationship between DM and mortality.
Methods The relationship between DM and six-month clinical outcome was assessed in
a series of 1,071 patients with AMI who underwent primary PCI. DM was considered
present if the diagnosis had been done before admission. Patients with DM were catego-
rized based on insulin/noninsulin treatment. The efficacy of reperfusion was assessed by
ST-segment resolution analysis at 30 min after infarct artery recanalization.
Results Out of 1,071 patients, 903 (84%) were non-DM and 168 had DM (16%). Among
DM patients, 86 (51%) patients had insulin-requiring DM. Insulin-requiring DM patients
had a worse risk profile as compared to the one of the other groups. Insulin-requiring DM
patients were older, more frequently women, had a greater incidence of cardiogenic
shock, 3-vessel disease and chronic occlusion. Primary PCI success was 97% in non-
DM patients, 98% in insulin-requiring DM patients and 94% in non-insulin-requring DM
patients. Early ST-segment resolution rate was lower in insulin-requiring DM patients
(52%) as compared to the other DM patients (78%), and non-DM patients (76%; p <
0.001). The 6-month mortality rate was 26% in insulin-requiring DM patients, 7% in non-
DM patients, and 4% in non-insulin-requiring DM patients (p < 0.001). Multivariate analy-
sis showed insulin-requiring DM to be independently related to the risk of death (HR
1.94, 95% CI 1.17-3.21, p = 0.010).Conclusions Insulin-requiring DM is a strong predic-
tor of mortality in patients undergoing PCI for AMI, and this relationship may be explained
by a less effective myocardial reperfusion despite mechanical restoration of a normal epi-
cardial flow in most patients.
1022-84 Survival Benefits of Primary Angioplasty Over 
Thrombolysis After Adjustment for Percutaneous 
Transluminal Coronary Angioplasty Related Time Delay
Giuseppe Tarantini, Angelo Ramondo, Massimo Napodano, Paolo Buja, Giambattista 
Isabella, Claudio Bilato, Renato Razzolini, Sabino Iliceto, University of Padua, Padua, 
Italy
Time to treatment remains a critical determinant of outcome after acute myocardial inf-
arction regardless of the strategy of reperfusion used. We investigated the relationship
between primary angioplasty (PTCA)-related delay and the benefits of PTCA, by review-
ing the results of randomized trials comparing PTCA with thrombolytic therapy (Rx). The
SHOCK trial was not considered in our analysis, Akhras’s trial was excluded because the
full data set was not available. DANAMI 2 study was considered as two separated sub-
studies (invasive and referral centers). We calculated the following:
PTCA - related delay = median “door to balloon” time – median “door to needle” time
Survival benefit= 30 day mortality after Rx – 30 day mortality after PTCA. Relationship
between delay and benefit was assessed by linear regression. Reported PTCA - related
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delay ranged from 7 to 104 minutes, while absolute survival benefit ranged from –4
(favoring Rx) to 15 (favoring PTCA). The survival benefit decreased as the PTCA-related
delay increased (figure). After the exclusion of AIR PAMI trial (longest delay and high risk
patients) equivalence of survival rates between PTCA and Rx was reached for a PTCA
related delay of 63 minutes: change in benefit per 10-minutes delay was 1 % (P=0.01). In
clinical trials with short PTCA-related delays, PTCA produced better outcomes, while tri-
als with longer delays favored Rx. At experienced institutions and for high risk patients,
however, PTCA is probably still preferable, even when delay is longer.
1022-85 Glucose-Insulin-Potassium Infusion Improves 
Myocardial Salvage in Diabetic Patients With Acute 
Myocardial Infarction Treated With Reperfusion Therapy
Jürgen Pache, Joerg Hausleiter, Adnan Kastrati, Julinda Mehilli, Hildegard Bolwein, 
Helmut Schühlen, Josef Dirschinger, Albert Schoemig, 1. Medizinische Klinik rechts der 
Isar, Munich, Germany, Deutsches Herzzentrum Muenchen, Munich, Germany
Patients (pts) with acute myocardial infarction (AMI) who receive reperfusion therapy
might have some benefit from glucose-insulin-potassium infusion (GIK). GIK is expected
to enhance myocardial salvage obtained with reperfusion. The objective of this subgroup
analysis of the randomized Reevaluation of Intensified Venous Metabolic Support for
Acute Infarct Size Limitation (REVIVAL) trial was to assess whether GIK improves myo-
cardial salvage in various subsets of pts.
We randomized 312 patients with AMI to receive either GIK infusion for 24 hours (GIK
group, n=155) or no GIK (control group, n=157). The primary endpoint of the study was
salvage index (proportion of myocardium at risk salvaged by therapy) as measured by
technetium Tc 99m sestamibi scintigraphic studies performed before and 7-10 days after
therapy. Various subsets of pts (fig) were analyzed according to their difference in sal-
vage index.
In the overall pts group salvage index was 0.5 in the GIK group and 0.48 in the control
group (p=0.96). The subgroup analysis is shown in the figure.
The results of this subgroup analysis demonstrate that GIK enhance myocardial salvage
only in pts with diabetes. 
1022-86 Association of Inflammation and Benefit of Statins in 
Patients With Acute Myocardial Infarction
Kunihiro Kinjo, Hiroshi Sato, Yozo Ohnishi, Eiji Hishida, Daisaku Nakatani, Hiroya 
Mizuno, Masahiko Shimizu, Masatsugu Hori, Osaka University Graduate School of 
Medicine, Suita, Japan
Background _ Inflammation as detected by elevated C-reactive protein (CRP) levels
predicts the risk of coronary events. The effect of inflammation on coronary risk has
shown to be attenuated by statin therapy in patients with stable coronary artery disease.
However, this effect of statin therapy for acute myocardial infarction (AMI) is unknown.
Methods and Results _ We studied 3508 survived AMI patients who enrolled in Osaka
Acute Coronary Insufficiency Study. CRP was measured during the stable phase (mean,
21 days after the onset). Patients with statin treatment at discharge had a lower 1-year
mortality than those without statin treatment (1.1% versus 3.2%, log rank, p<0.001). Mul-
tivariate Cox regression analysis revealed that statin treatment remained predictive of a
lower 1-year mortality rate (hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.15-
0.96). Although the 1-year mortality was not different among patients with and without
statin treatment in patients with low CRP, the 1-year mortality was higher in the patients
without statin treatment than in those with statin treatment in patients with high CRP. In
the presence of statin therapy, the HR for 1-year mortality was significantly reduced in
patients with high CRP (HR, 1.46, 95% CI, 0.15-14.5) to about the same degree as in
patients with low CRP and who did not receive statin therapy (HR, 2.53; 95% CI, 0.46-
13.8).
Conclusions _ Statin treatment at discharge is associated with reduced 1-year mortality
of patients with AMI. Furthermore, statin treatment significantly attenuates the increased
risk for 1-year mortality in patients with AMI. Measurement of CRP levels may improve
targeting of statin therapy in patients with AMI.
1022-87 Improvement of Long-Term Outcome in Acute 
Myocardial Infarction Over Time: Experiences From the 
Register of Information and Knowledge About Swedish 
Heart Intensive Care Admissions
Ulf Stenestrand, Lars Wallentin, Heart Center, University Hospital, Linkoping, Sweden, 
UCR, University Hospital, Uppsala, Sweden
Background: During the last years several new therapies, some very costly, have proven
in clinical trials to improve survival in patients with acute myocardial infarction (AMI). The
aim of this study was to evaluate if these new therapies have changed long term outcome
in a non selected CCU population of daily care patients.
Methods & Results: All patients admitted to participating CCUs were included. Clinical
background, admission status, medications, interventions, complications were recorded
for the years 1995-2001 including 1 year follow-up until the end of 2002 in 90% of the
Swedish hospitals. Among the CCU patients there were 73828 with AMI. In hospital and
long term mortality decreased for each studied year. The Kaplan-Meier curves indicate
that during the study period 1-year mortality has sunken from 21% to 16% in patients 66-
75 years (figure 1), 9% to 6% in patients below 65 years, and 39% to 35% in patients
older than 75 years.
Conclusion: This analysis supports that new therapies have helped to improve 1-year
survival in not only in selected trial patients but also in an unselected cohort of daily CCU
patients of all ages with AMI.
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1023-89 Chelation Therapy for Patients With Coronary Heart 
Disease: Findings From the Pilot to Assess Chelation 
Therapy
Gervasio A. Lamas, Alan Ackermann, Danielle Hollar, Paul Kurlansky, Joseph Vita, 
Charles H. Hennekens, Mount Sinai Medical Center-Miami Heart Institute, Miami Beach, 
FL, Boston University School of Medicine, Boston, MA
Background: Chelation therapy involves a series of intravenous infusions of dsodium
EDTA. Despite widespread use for the treatment of coronary heart disease (CHD), ran-
domized data on safety and benefits are relatively sparse. The Pilot for the Trial to Assess
Chelation Therapy (PACT) was a randomized, double-blind, placebo-controlled trial, com-
paring EDTA chelation with placebo infusions.
Methods: PACT randomized and followed 40 patients, 30 assigned to chelation therapy
infusions, and 10 to placebo infusions. All patients received 15 weekly infusions of chela-
tion or normal saline, plus low-dose vitamin supplementation. Laboratory safety data
were compared between groups on the last day of infusion. We also performed
endothelial function studies using brachial artery flow-mediated dilation expressed as
percent above baseline (FMD %).
Results: On the day of the last infusion, there were no significant differences between
the chelation and placebo groups for: creatinine (1.1 v 1.1), glucose (112 v 134), hemat-
